OBJECTIVE: Despite treatment advancements, disease-free survival of head and neck squamous cell carcinoma (HNSCC) has not significantly improved. This may be a result of tumor-fibroblasts interactions providing protective pathways for oncogenic cells to resist therapy. Further understanding of these relationships in HNSCC may improve effectiveness of targeted therapies. In this article, we investigated the role of several receptor tyrosine kinases (RTKs) in the interactions between HNSCC cells and supporting cells (fibroblasts). MATERIALS AND METHODS: HNSCC cell lines and human tumor samples were evaluated for FGFR1/2/3, and PDGF-beta expression levels. Cell lines (FADU, SCC1, OSC19, Cal27, SCC22A) were treated with a range of physiological concentrations of dovitinib and assessed for proliferation, cytotoxicity, and apoptosis. Mice bearing HNSCC xenografts were treated with dovitinib (20 mg/kg). RESULTS: Evaluation of HNSCC tumor specimens, cell lines and fibroblasts found variable expression of multiple RTKs (fibroblasts growth factor receptor, platelet derived growth factor receptor and vascular endothelial growth factor receptor) and their ligands, supporting previous theories of paracrine and autocrine signaling within the microenvironment. In a dose-dependent fashion, RTK inhibition reduced proliferation of HNSCC cell lines and fibroblast in vitro. When HNSCC cells were cocultured with fibroblasts, RTK inhibition resulted in a smaller reduction in the proliferation relative to untreated conditions. In vivo, RTK inhibition resulted in significant tumor regression and growth inhibition (p<0.05) and reduced the incidence of regional lymph node metastasis. CONCLUSION: Effective treatment of HNSCC, therefore, may require inhibition of multiple RTKs in order to adequately inhibit the microenvironment's various signaling pathways.
OBJECTIVE: Despite treatment advancements, disease-free survival of head and neck squamous cell carcinoma (HNSCC) has not significantly improved. This may be a result of tumor-fibroblasts interactions providing protective pathways for oncogenic cells to resist therapy. Further understanding of these relationships in HNSCC may improve effectiveness of targeted therapies. In this article, we investigated the role of several receptor tyrosine kinases (RTKs) in the interactions between HNSCC cells and supporting cells (fibroblasts). MATERIALS AND METHODS: HNSCC cell lines and humantumor samples were evaluated for FGFR1/2/3, and PDGF-beta expression levels. Cell lines (FADU, SCC1, OSC19, Cal27, SCC22A) were treated with a range of physiological concentrations of dovitinib and assessed for proliferation, cytotoxicity, and apoptosis. Mice bearing HNSCC xenografts were treated with dovitinib (20 mg/kg). RESULTS: Evaluation of HNSCC tumor specimens, cell lines and fibroblasts found variable expression of multiple RTKs (fibroblasts growth factor receptor, platelet derived growth factor receptor and vascular endothelial growth factor receptor) and their ligands, supporting previous theories of paracrine and autocrine signaling within the microenvironment. In a dose-dependent fashion, RTK inhibition reduced proliferation of HNSCC cell lines and fibroblast in vitro. When HNSCC cells were cocultured with fibroblasts, RTK inhibition resulted in a smaller reduction in the proliferation relative to untreated conditions. In vivo, RTK inhibition resulted in significant tumor regression and growth inhibition (p<0.05) and reduced the incidence of regional lymph node metastasis. CONCLUSION: Effective treatment of HNSCC, therefore, may require inhibition of multiple RTKs in order to adequately inhibit the microenvironment's various signaling pathways.
Authors: Candice Wakulich; Linda Jackson-Boeters; Tom D Daley; George P Wysocki Journal: Oral Surg Oral Med Oral Pathol Oral Radiol Endod Date: 2002-05
Authors: Nils H Nicolay; Eva Sommer; Ramon Lopez Perez; Ute Wirkner; Tilman Bostel; Anthony D Ho; Michael Lahn; Jürgen Debus; Rainer Saffrich; Peter E Huber Journal: Strahlenther Onkol Date: 2014-05-27 Impact factor: 3.621
Authors: Michael M Fisher; Gopika SenthilKumar; Rong Hu; Steve Goldstein; Irene M Ong; Margot C Miller; Sean R Brennan; Saakshi Kaushik; Lindsey Abel; Kwangok P Nickel; Gopal Iyer; Paul M Harari; Randall J Kimple; Andrew M Baschnagel Journal: Int J Radiat Oncol Biol Phys Date: 2020-04-13 Impact factor: 7.038
Authors: Till Sebastian Clauditz; Arne Böttcher; Henning Hanken; Kerstin Borgmann; Guido Sauter; Waldemar Wilczak; Tobias Grob; Adrian Münscher Journal: J Cancer Res Clin Oncol Date: 2017-10-11 Impact factor: 4.553
Authors: Norbertus A Ipenburg; Koos Koole; K Seng Liem; Pauline M W van Kempen; Ron Koole; Paul J van Diest; Robert J J van Es; Stefan M Willems Journal: Target Oncol Date: 2016-02 Impact factor: 4.493
Authors: Barbara Mognetti; Giuseppe La Montagna; Maria Giulia Perrelli; Pasquale Pagliaro; Claudia Penna Journal: J Cell Mol Med Date: 2013-01-10 Impact factor: 5.310
Authors: Veronika Maria Metzler; Christian Pritz; Anna Riml; Angela Romani; Raphaela Tuertscher; Teresa Steinbichler; Daniel Dejaco; Herbert Riechelmann; József Dudás Journal: Tumour Biol Date: 2017-11